A Mathematical Model on Vorinostat (Histone Deacetylase Inhibitor) in Combination with Radiotherapy

G. Komahan, AVVM Sri Pushpam College, Poondi; R. Lalitha ,AVVM SRI PUSHPAM COLLEGE,POONDI

Histone Deacetylase Inhibitors, Radiation Therapy, Mathematical Model

There are four main and most types of cancer treatments, which are surgery, chemotherapy, radiotherapy, and immunotherapy. In this paper, we consider cancer treatment by radiotherapy. Radiation therapy is a treatment procedure that uses radiation to kill tumor cells. The Histone deacetylases inhibitor (HDAC) Vorinostat (suberoylanilide hydroxamic acid or SAHA) combination with radiotherapy blocks cancer cell proliferation. In this study we developed and analyse Mathematical model for tumor growth and histone deacetylase inhibitor, in combination with radiotherapy then we analyse the stability of equilibria. And fitting Patient 1 data to numerical simulation for locally weighted smoothing linear regression.
    [1] Hahnen E, Hauke J, Tränkle C, Eyüpoglu IY, Wirth B, Blümcke I (Feb 2008). "Histone deacetylase inhibitors: possible implications for neurodegenerative disorders". Expert Opinion on Investigational Drugs. 17 (2): 169–84. doi:10.1517/13543784.17.2.169. PMID 18230051. [2] P. Hahnfeldt, D. Panigrahy, J. Folkman and L. Hlatky, Tumor development under angio- genic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy, Cancer Research, 59 (1999), 4770–4775. [3] Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H (2003) Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9: 3578–3588 [4] Lane AA, Chabner BA: Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009, 32:5459-5468. [5] Merck Research Laboratories, Department of Cancer Biology and Therapeutics, BMB9-101, 33 Avenue Louis Pasteur, Boston, MA 02115, USA [6] Miller TA, Witter DJ, Belvedere S (Nov 2003). "Histone deacetylase inhibitors". Journal of Medicinal Chemistry. 46 (24): 5097–116. doi:10.1021/jm0303094. PMID 14613312 [7] Mwakwari SC, Patil V, Guerrant W, Oyelere AK (2010). "Macrocyclic histone deacetylase inhibitors". Curr Top Med Chem. 10 (14): 1423–40. doi:10.2174/156802610792232079. PMC 3144151 . PMID 20536416 [8] L.G. de Pillis, W.Gu, A.E. Radunskaya, Mixed Immunotherapy and Chemotherapy of tumors: Modeling, Applications and Biological interpretations, 2005. [9] S.T.R. Pinho a,∗, F.S. Bacelar a,b, R.F.S. Andradea, H.I. Freedmanc A mathematical model for the effect of anti-angiogenic therapy in the treatment of cancer tumours by chemotherapy Nonlinear Analysis: Real World Applications 14 (2013) 815–828 [10] "Scientists 'reverse' memory loss". BBC News. 2007-04-29. Retrieved 2007-07-08. [11] Siegel D, Hussein M, Belani C, et al. Vorinostat in solid and hematologic malignancies. J. Hematol. Oncol. 2009;2:31. [PMC free article] [PubMed] [12] Wagner JM, Hackanson B, Lübbert M, Jung M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics. 2010;1 (3-4:117–136. [PMC free article] [PubMed].
Paper ID: GRDJEV03I030026
Published in: Volume : 3, Issue : 3
Publication Date: 2018-03-01
Page(s): 35 - 39